Jan 22, 2025 · NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2024. "2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating pipeline and industry-leading investments in innovation,” said Joaquin Duato, Chairman and Chief Executive Officer, …

This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy.Use of this site constitutes your consent to ...

Note: Your browser does not support JavaScript, Press Continue to proceed...

Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives.

A travers le monde, Johnson & Johnson Innovation cherche à avoir un impact positif sur la santé humaine grâce à des collaborations synergiques avec des partenaires stratégiques publics ou privés.

Discover exciting career opportunities at Johnson & Johnson in Malaysia. Search job openings and apply now to join a global leader in healthcare innovation.

2024 Key events. Major US/EU approvals and submissions and phase 2/3 clinical data presentations being planned or achieved for the year. Learn more

Submit complaints about Johnson & Johnson products.

Elevate your career with J&J. Discover global job opportunities to drive innovation, impact lives and grow in a supportive, mission-driven culture.

Jan 13, 2025 · New Brunswick, N.J. and Bedminster, N.J., January 13, 2025 – Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the …